Skip to main content

Table 1 Patients’ characteristics at initiation of tocilizumab and during follow-up

From: Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial

  At initiation of tocilizumab
N = 13
At 1 month
N = 13
At 2 months
N = 13
At 3 months
N = 13
At 4 months
N = 12
At 5 months
N = 13
At 6 months
N = 13
At 9 months
N = 13
At 12 months
N = 12
At 15 months
N = 10
At 18 months
N = 11
Vascular manifestations 13 (100) 9 (69) 10 (100) 8 (62) 4 (33) 7 (54) 7 (54) 7 (54) 7 (58) 4 (40) 4 (36)
-Arm claudication 5 (38) 3 (23) 4 (30) 2 (15) 2 (15) 4 (30) 3 (23) 4 (30) 2 (17) 2 (20) 2 (18)
-Lower limb claudication 3 (23) 1 (8) 0 1 (8) 0 0 1 (8) 2 (15) 0 0 0
-Anisotension 7 (54) 7 (54) 8 (62) 4 (30) 3 (23) 5 (38) 4 (30) 4 (30) 5 (42) 3 (30) 3 (27)
-Carotidynia 9 (69) 1 (8) 3 (23) 1 (8) 0 2 (15) 3 (23) 3 (23) 3 (23) 2 (20) 1 (9)
Constitutional manifestations 5 (38) 2 (15) 3 (23) 1 (8) 2 (17) 2 (15) 4 (33) 1 (8) 1 (8) 2 (20) 0
-Arthromyalgias 3 (23) 0 1 (8) 1 (8) 0 1 (8) 2 (15) 4 (31) 0 0 0
-Fever/asthenia 3 (23) 2 (15) 1 (8) 1 (8) 2 (15) 2 (15) 4 (31) 1 (8) 1 (8) 1 (8) 0
NIH score 3 [3–4] 1 [0–2] 1 [0–2] 1 [0–3] 1 [0–4]   1 [0–3]
ITAS 2010/ITAS-A 5 [2–7]/7 [4–10] 2 [0–5]/2 [0–5] 3 [0–8]/4 [1–15] 3 [0–8]/4 [0–11] 2 [0–4]/2.5 [0–34]   1 [0–7]/3 [0–9]
Subjective disease activity by practitioner
-Remission 5 (38) 5 (38) 7 (54) 7 (54) 9 (69) 8 (62) 7 (54) 7 (58) 6 (60) 7 (64)
-Active 13 (100) 0 0 1 (8) 0 2 (15) 2 (15) 3 (23) 2 (16) 4 (40) 4 (36)
-Stable 7 (54) 7 (54) 5 (38) 6 (50) 2 (15) 2 (15) 3 (23) 3 (25) 0 0
C-reactive protein (mg/L) 16 [3–98] 1 [0–14] 1 [0–10] 0 [0–2] 1 [0–17] 1 [0–17] 1 [0–12] 4 [0–53] 3 [0–28] 10 [0–42] 14 [0–45]
Fibrinogen (g/l) 5 [2.8–8] 2 [1–5] 2 [2–6] 2 [0–4.5] 2 [1.5–5] 2 [1.5–5] 2 [1–3] 3 [2–7] 3 [1–5] 4 [2–7] 5 [2–6]
Prednisone (n; %) 13 (100) 13 (100) 13 (100) 13 (100) 12 (100) 13 (100) 7 (54) 7 (54) 6 (50) 7 (70) 7 (64)
Prednisone (mg/day) 45 [35–65] 25 [15–40] 20 [15–30] 10 [10–25] 7.5 [5–17.5] 5 [2.5–30] 5 [0–10] 3 [0–30] 2.5 [0–15] 3.5 [0–10] 3 [0–10]
Immunosuppressive drugs 0 0 0 0 0 0 0 MTX (n = 2) /Ada (n = 1)/Inf (n = 1) MTX (n = 2)/Ada (n = 1)/Inf (n = 1)/Toci (n = 1) MTX (n = 2)/MTX+ Ada (n = 1)/MTX+ Inf (n = 1)/Toci (n = 2) MTX + Ada (n = 2) /Uste (n = 1)/MTX + Toci (n = 1)/Toci (n = 2)/Aza (n = 1)
NIH < 2
+prednisone < 7.5 mg/day 9 (69) 7 (54) 6 (50) 9 (90%) 4 (36)
< 10 mg/day        11 (85) 9 (69) 9 (75) 10 (100) 6 (55)
  1. Values are presented as medians [ranges] and numbers (frequencies)
  2. Inf infliximab, Toci tocilizumab, Uste ustekinumab, Ada adalimumab, Aza azathioprine, MTX methotrexate
  3. *p < 0.0001 between baseline and all visits during the follow-up (Kruskal-Wallis tests or Fisher’s test)
\